Last reviewed 2026-05-14 · How we verify

Biocodex — Portfolio Competitive Intelligence Brief

Biocodex pipeline: 2 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

Therapeutic area mix

• Diagnostics · 2
• Gastroenterology · 1
• Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

1. BioBalance Corporation · 1 shared drug class
2. BrainCells Inc. · 1 shared drug class
3. CD Pharma India Pvt. Ltd. · 1 shared drug class
4. CHU de Quebec-Universite Laval · 1 shared drug class
5. Chuncheon Sacred Heart Hospital · 1 shared drug class
6. Dow University of Health Sciences · 1 shared drug class
7. Federico II University · 1 shared drug class
8. Aga Khan University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Biocodex:

• Biocodex pipeline updates — RSS
• Biocodex pipeline updates — Atom
• Biocodex pipeline updates — JSON

Cite this brief

Drug Landscape (2026). Biocodex — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biocodex. Accessed 2026-05-14.

Related

• Biocodex full company profile
• All CI briefs
• Build a custom feed